Transdermal Buprenorphine Induced Respiratory Acidosis in a Post TKR patient A Rare Case
Keywords:
respiratory acidosis, buprenorphine, transdermal patch, respiratory depression
Abstract
Post-operative pain management consists of a cocktail of drugs ranging from Nsaids, Opioids and Non-opioids. Transdermal Buprenorphine patch is commonly used in pain management of post-operative cases, musculoskeletal pain, cancerous and non-tumorous conditions. Buprenorphine is safely used because of its partial intrinsic activity and slow dissociation on Mu (µ) receptor causing prolonged analgesic effect with a ceiling for respiratory depression. Buprenorphine is commonly used in elderly patients and in patients with chronic renal failure. We report a probable case of buprenorphine patch induced respiratory depression and sedation leading to respiratory acidosis. Respiratory acidosis was managed symptomatically with oxygen therapy and removal of transdermal buprenorphine patch lead to the reversal of clinical condition. Awareness of this possible side effect of buprenorphine patch and unwarranted use should be avoided.
Downloads
- Article PDF
- TEI XML Kaleidoscope (download in zip)* (Beta by AI)
- Lens* NISO JATS XML (Beta by AI)
- HTML Kaleidoscope* (Beta by AI)
- DBK XML Kaleidoscope (download in zip)* (Beta by AI)
- LaTeX pdf Kaleidoscope* (Beta by AI)
- EPUB Kaleidoscope* (Beta by AI)
- MD Kaleidoscope* (Beta by AI)
- FO Kaleidoscope* (Beta by AI)
- BIB Kaleidoscope* (Beta by AI)
- LaTeX Kaleidoscope* (Beta by AI)
How to Cite
References
Wilcock Andrew, Twycross Robert (2013) Therapeutic Reviews Journal of Pain and symptom management. 45(5), 939-949.
R. Raffa, J. Pergolizzi (2014) A modern analgesics pain 'pyramid'. 39, 4e6.
Davis MP (2012) Twelve reasons for considering buprenorphine as frontline analgesic in the management of pain. 10, 209-19.
Budd K (1981) High dose buprenorphine for postoperative analgesia. 36, 900-903.
Pergolizzi J, Aloisi AM, Dahan A, Filitz J, Langford R, Likar R (2010) Current knowledge of buprenorphine and its unique pharmacological profile. 10, 428e50.
Berner B, John VA (1994) Pharmacokinetic characterization of transdermal delivery systems. 26, 121-34.
Likar R (2006) Transdermal buprenorphine in the management of persistent pain-safety aspects Therapeutics and Clinical Risk Management. 2(1), 115-125.
K. Budd (2003) Buprenorphine and the transdermal system: the ideal match in pain management.
Likar R, Vadlau EM, Breschan C, Kager I, Korak- M, Ziervogel G (2008) Comparable analgesic efficacy of transdermal buprenorphine in patients over and under 65 years of age. 24, 536e43.
Steiner DJ, Sitar S, Wen W (2011) Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebocontrolled study. 42, 903e17.
Kamp-Jensen Bach V, Jensen N-H (1991) Buprenorphine and sustained release morphine - effect and side-effects in chronic use. 4, 87-93.
G. Kress (2009) Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine European Journal of Pain. 13(3), 219-230. https://doi.org/10.1016/j.ejpain.2008.04.011
K. Budd (2002) Buprenorphine: a review In: Evidence based medicine in practice. 2002, 1-24.
Scholten Pergolizzi V Joseph, Smith Kevin, Scott James, Henningfeild Wills C Jenna (2015) The Unique role of transdermal buprenorphine in the global chronic pain epidemic Acta Anaesthesiologica Taiwanica. 53(2), 71-76. https://doi.org/10.1016/j.aat.2015.06.001
P. Naik (2017) Safety and efficacy of transdermal buprenorphine versus oral tramadol for the treatment of post-operative pain following surgery for fracture neck of femur: A prospective, randomised clinical study. 61, 225.
Published
2018-02-14
Issue
Section
License
Copyright (c) 2018 Authors and Global Journals Private Limited

This work is licensed under a Creative Commons Attribution 4.0 International License.